Value added utilization of by-product electric furnace ferronickel slag as construction materials: A review

This paper reviews the potential use of electric furnace ferronickel slag (FNS) as a fine aggregate and binder in Portland cement and geopolymer concretes. It has been reported that the use of FNS as a fine aggregate can improve the strength and durability properties of concrete. Use of some FNS aggregates containing reactive silica may potentially cause alkali-silica reaction (ASR) in Portland cement concrete. However, the inclusion of supplementary cementitious materials (SCM) such as fly ash and blast furnace slag as partial cement replacement can effectively mitigate the ASR expansion. When finely ground FNS is used with cement, it shows pozzolanic reaction, which is similar to that of other common SCMs such as fly ash. Furthermore, 20% FNS powder blended geopolymer showed greater strength and durability properties as compared to 100% fly ash based geopolymers. The utilization of raw FNS in pavement construction is reported as a useful alternative to natural aggregate. Therefore, the use of by-product FNS in the construction industry will be a valuable step to help conservation of natural resources and add sustainability to infrastructures development. This paper presents a comprehensive review of the available results on the effects of FNS in concrete as aggregate and binder, and provides some recommendations for future research in this field

International Nosocomial Infection Control Consortium report, data summary of 50 countries for 2010-2015: Device-associated module

•We report INICC device-associated module data of 50 countries from 2010-2015.•We collected prospective data from 861,284 patients in 703 ICUs for 3,506,562 days.•DA-HAI rates and bacterial resistance were higher in the INICC ICUs than in CDC-NHSN's.•Device utilization ratio in the INICC ICUs was similar to CDC-NHSN's. Background: We report the results of International Nosocomial Infection Control Consortium (INICC) surveillance study from January 2010-December 2015 in 703 intensive care units (ICUs) in Latin America, Europe, Eastern Mediterranean, Southeast Asia, and Western Pacific. Methods: During the 6-year study period, using Centers for Disease Control and Prevention National Healthcare Safety Network (CDC-NHSN) definitions for device-associated health care-associated infection (DA-HAI), we collected prospective data from 861,284 patients hospitalized in INICC hospital ICUs for an aggregate of 3,506,562 days. Results: Although device use in INICC ICUs was similar to that reported from CDC-NHSN ICUs, DA-HAI rates were higher in the INICC ICUs: in the INICC medical-surgical ICUs, the pooled rate of central line-associated bloodstream infection, 4.1 per 1,000 central line-days, was nearly 5-fold higher than the 0.8 per 1,000 central line-days reported from comparable US ICUs, the overall rate of ventilator-associated pneumonia was also higher, 13.1 versus 0.9 per 1,000 ventilator-days, as was the rate of catheter-associated urinary tract infection, 5.07 versus 1.7 per 1,000 catheter-days. From blood cultures samples, frequencies of resistance of Pseudomonas isolates to amikacin (29.87% vs 10%) and to imipenem (44.3% vs 26.1%), and of Klebsiella pneumoniae isolates to ceftazidime (73.2% vs 28.8%) and to imipenem (43.27% vs 12.8%) were also higher in the INICC ICUs compared with CDC-NHSN ICUs. Conclusions: Although DA-HAIs in INICC ICU patients continue to be higher than the rates reported in CDC-NSHN ICUs representing the developed world, we have observed a significant trend toward the reduction of DA-HAI rates in INICC ICUs as shown in each international report. It is INICC's main goal to continue facilitating education, training, and basic and cost-effective tools and resources, such as standardized forms and an online platform, to tackle this problem effectively and systematically